CBLN2

Across TCGA pan-cancer cohorts, CBLN2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CBLN2 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CBLN2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CBLN2 expression acts as an unfavorable survival marker, although some lineages such as LUSC and UCEC show a favorable association.

LUSC, STAD, and UCEC are the cancer types where CBLN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.834	0.378	.006	13	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
UCEC	DFS	Median	II,III,IV	0.929	0.304	.013	10	view →
SARC	DFS	Median	All	0.094	0.611	.001	9	view →
LIHC	OS	Median	All	0.098	0.774	.001	9	view →
PRAD	DFS	Median	All	0.111	0.886	<.001	8	view →
COAD	DFS	Median	All	0.161	0.525	.002	7	view →
SKCM	DFS	Median	IV	0.040	0.432	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CBLN2–LUSC (DFS)

Open the LUSC breakdown →